Compare Biogen Inc (BIIB) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Kimberly Clark Corp — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Kimberly Clark Corp trades at $106.78 (market cap $35.46B). The key difference: Kimberly Clark Corp is the larger of the two by market cap, and Kimberly Clark Corp pays a 4.79% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | KMB | |
|---|---|---|
Market Cap | $28.34B | $35.46B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $136.77 |
52-Week Low | $122.68 | $93.05 |
Enterprise Value | $30.62B | $42.00B |
Dividend Yield | — | 4.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Kimberly-Clark (KMB) trades at $110.18, down 1.98% on the day, with strong technical support at $108 and resistance at $114. The company demonstrates solid fundamentals with Q1 2026 EPS beating expectations at $1.97 versus $1.93, maintaining a consistent earnings beat streak. Recent business developments include the Arbex joint venture launch and pending Kenvue acquisition, positioning for strategic growth in the consumer goods sector.
KMB offers stable dividend income with a 4.5% yield and strong profitability metrics (12.8% net margin, 146.29% ROE), though elevated P/E (21.31) and P/B (20.36) ratios suggest premium valuation. Risks include consumer sentiment pressures and input cost inflation, but analyst consensus targets $112.33 with 32% buy ratings supporting moderate upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
